The Clinical Relevance and Significance of New Diagnostic Options in patients with unexplained bleeding - The CRESCENDO-study

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 330 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•Patients of all ages;
•Patients with a significant history of bleeding tendency according to physician opinion or abnormal bleeding score based on a BAT
•o with no defined diagnosis after routine testing (see appendix 4 of the research protocol),
•o with a heterozygous factor deficiency or low Von Willebrand Factor levels that do not
•correspond with the experienced bleeding tendency,
•o with aberrant laboratory results not fitting a diagnosis;
•Informed consent should be provided prior to any study specific procedure.

•Patients with a defined bleeding disorder after routine testing (see appendix 4 of the research protocol, except when they serve as controls for the trombocytopathy arm);
•Patients under therapy with anticoagulants and / or antiplatelet and / or anti-inflammatory agents whom cannot stop their medication during the diagnostic work-up;
•Patients with thrombocytopenia < 80 x 109/L (with exception to the patients with suspected or volunteers in the control group with a proven platelet disorder);
•Patients with a bleeding tendency due to an acquired platelet function disorder (e.g. idiopathic thrombocytopenic purpura * ITP);
•Patients with impaired liver function, eg a documented liver cirrhosis or signs of acute liver failure;
•Women that are pregnant or up to three months postpartum;
•Patients who are inable to give informed consent.

发起方